The judge weighing the legal costs sought to be deducted from a $300 million settlement in pelvic mesh class actions against Johnson & Johnson has questioned Shine Lawyers’ bid to make group members pay $32 million in interest incurred on a loan the firm took out at “credit card” rates.
The Federal Court’s recently retired top judge has landed on his feet with his appointment by the court as referee to determine which of a group of competing firms should dole out a $300 million settlement that resolved the J&J pelvic mesh class actions.
A contradictor in two pelvic mesh class actions against Johnson & Johnson and unit Ethicon has told the court of the “extraordinary amount of group member unhappiness” following approval of a $300 million settlement – the largest in the history of Australian product liability group proceedings.
Shine Lawyers can deduct 50 per cent of its fees and all of its costs from a $300 million settlement in pelvic mesh class actions against Johnson & Johnson while a judge mulls whether the law firm’s total bill is fair and reasonable.
A judge has approved a $300 million settlement in two pelvic mesh class actions against Johnson & Johnson and unit Ethicon — the largest settlement in the history of Australian product liability group proceedings — but a $100 million deduction for legal costs has yet to get the greenlight.
A class action by property owners against the manufacturer and supplier of alleged combustible cladding has lost a bid for sales figures to estimate the value of their claims as the parties head into settlement negotiations next month.
Sixteen law firms and accounting firms have thrown their hat in the ring to administer a $300 million settlement in two class actions against Johnson & Johnson over pelvic mesh devices that injured thousands of women.
A contradictor appointed in two pelvic mesh class actions against Johnson & Johnson has blasted a $300 million settlement, calling it “massively” short of what is owed to group members, after a judge preliminarily found the sum was not fair and reasonable.
Regenerative medicine company Mesoblast has hit back at a shareholder class action over its Remestemcel-L treatment for COVID-19, saying that some group members are barred from bringing claims because of a settlement reached in a US class action.
After initial qualms, a judge has signed off on a $29.5 million settlement in a class action against recycling company Sims that includes a “staggering” $8.5 million in legal costs and an insurance policy buffering the funder from adverse costs.